The Male Hypogonadism Market is expected to register a CAGR of 5.1% during the forecast period. Male hypogonadism or testosterone deficiency is a condition in which the body doesn't produce enough of the hormone that plays a key role in development and masculine growth during puberty or enough sperm or both. Hypogonadism may occur at any age, and the consequences differ, according to when it starts. In adult men, within a few weeks of the onset of testosterone deficiency symptoms begin. Hypogonadism may increase the risk for type 2 diabetes, cardiovascular disease, premature death in older men, metabolic syndrome, and Alzheimer’s disease.
According to Boston University School of Medicine, approximately 4 to 5 million men in the United States, are affected with hypogonadism and low testosterone levels are commonly seen in older males. More than 60% of men over 65 years of age have free testosterone levels below the normal values of men between 30 to 35 years of age. A Study published in the Indian Journal of Endocrinology and Metabolism in the year 2017, estimates that prevalence of hypogonadism in type 2 diabetes patients was found to be 20.7%. Furthermore, the prevalence rate of hypogonadism in patients with type 2 diabetes was moderate with highest number of patients belonging to age group 50-59 year.
Increase in incidence and prevalence of hypogonadism, technological advancements in male hypogonadism therapy and rise in awareness about hypogonadism and its treatment option are the key driving factors in male hypogonadism market.
Key Market Trends
Gonadotropin-Releasing Hormones Therapy Segment is Expected to Hold a Major Market Share in the Male Hypogonadism Market
- Gonadotropin releasing hormone stimulates to release follicle-stimulating hormone, and luteinizing hormone, which helps in regulating the gametogenic and steroidogenic functions of the gonads in males.
- As per European Association of Urology 2016 report, incidence of hypogonadism in middle-aged men, varied from 2.1% to 12.8%, men aged 40-79 varied form 2.1% to 5.7%, in Europe. In addition, hypogonadism is more prevalent in older men with obesity and in men with a poor health status.
- Gonadotropin-releasing hormones therapy segment holds a significant market share in male hypogonadism market and is anticipated to show similar trend over the forecast period. Moreover, due to rise in adoption of this therapy with increasing cases of hypogonadism in men are the key driving factors in the Gonadotropin-releasing hormones therapy segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global male hypogonadism market due to increasing incidence and prevalence of hypogonadism and rise in awareness about hypogonadism and its treatment option in this region. According to the study published in European Association of Urology Journal in the year 2017, testosterone prescription trends in the United States estimated an increase between 1.8 and 4-fold over the last two decades (1997 - 2017). Furthermore, increasing research and development coupled with technologically advanced products and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
The Male Hypogonadism Market is fragmented competitive and consists of a several major players. Some of the players in the market focus on technologically and innovation of advanced products to meet the growing demand of the product. Some of the companies which are currently dominating the market are Endo International Plc, AbbVie Inc, Pfizer Inc, Allergan Plc, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Bayer AG, Merck & Co., Inc, Sun Pharmaceutical Industries Limited and Ferring Holding S.A.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Cases of Male Hypogonadism Worldwide
4.2.2 Technological Advancements in Male Hypogonadism Therapy
4.2.3 Growing Awareness Among Individuals Regarding Hypogonadism Treatment
4.3 Market Restraints
4.3.1 High Side Effects Associated with Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Testosterone Replacement Therapy
5.1.2 Gonadotropin-Releasing Hormones Therapy
188.8.131.52 Human Chorionic Gonadotropin (hCG)
184.108.40.206 Follicle-stimulating Hormone (FSH)
220.127.116.11 Gonadotropin-releasing Hormone (GnRH)
18.104.22.168 Other Gonadotropin Replacement Therapies
5.2 By Application
5.2.1 Kallmann Syndrome
5.2.2 Klinefelters Syndrome
5.2.3 Pituitary Disorders
5.2.4 Other Applications
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6.1.1 Endo International Plc
6.1.2 AbbVie Inc
6.1.3 Pfizer Inc
6.1.4 Allergan Plc
6.1.5 Teva Pharmaceutical Industries Ltd
6.1.6 Eli Lilly and Company
6.1.7 Bayer AG
6.1.8 Merck & Co., Inc
6.1.9 Sun Pharmaceutical Industries Limited
6.1.10 Ferring Holding S.A
A selection of companies mentioned in this report includes:
- Endo International Plc
- AbbVie Inc
- Pfizer Inc
- Allergan Plc
- Teva Pharmaceutical Industries Ltd
- Eli Lilly and Company
- Bayer AG
- Merck & Co., Inc
- Sun Pharmaceutical Industries Limited
- Ferring Holding S.A